IMM- H007は,AMPKαを活性化させ,高コレステロール血症を緩和することによって,肝臓のコレステロールとトリグリセリド代謝を促進する
Jiaqi Li1, Mingchao Wang2, Kai Qu2
1Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Acta pharmaceutica Sinica. B
|September 2, 2025
まとめ
AMPKアゴニストであるIMM- H007は,高コレステロール血症におけるコレステロールとトリグリセリド代謝を改善する. 肝臓のコレステロールの吸収と胆酸の変換を高め 脂肪肝を予防します
科学分野:
- 生物化学
- 代謝 疾患
- 薬理学について
背景:
- 高コレステロール血症は動脈硬化症の主要な危険因子です.
- IMM-H007のようなAMPKアゴニストは代謝疾患において有望である.
- 高コレステロール血症の代謝に対するIMM- H007の作用は十分に理解されていません.
研究 の 目的:
- コレステロールとトリグリセリドの代謝に対するIMM-H007の影響を調査する.
- IMM-H007がこれらの代謝過程を調節する特定のメカニズムを解明する.
主な方法:
- 超コレステロール血症と動脈硬化症をモデル化するために,Apoe-/−とLdlr-/−のマウスを利用した.
- 肝細胞特異的なAmpka1/ 2ノックアウトマウスを使用し,高コレステロールの食事とAAV- PCSK9注射で高コレステロールと動脈硬化を引き起こした.
- 脂質代謝への影響を評価するためにIMM-H007を投与した.
主要な成果:
- IMM- H007は,高コレステロール症のマウスのコレステロールとトリグリセリド代謝を有意に改善しました.
- メカニズム的には,IMM-H007はAMPKα1/2-LDLR経路をアップ調節し,肝臓のコレステロール吸収を増加させた.
- IMM- H007はAMPKα1- FXR経路を活性化させ,コレステロールを胆汁酸に変換し,AMPKα1/ 2- ATGL経路を活性化させ,肝硬変を予防した.
結論:
- IMM- H007は高コレステロール血症と動脈硬化症の治療の可能性を示しています.
- IMM- H007によるAMPKαの活性化は,脂質代謝に対する有益な効果の鍵です.
関連する概念動画
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
Cholesterol: Significance and Regulation
669
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
669
cAMP-dependent Protein Kinase Pathways
6.6K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
Hepatic Drug Excretion: Influencing Factors
214
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
214
Hepatic Drug Clearance: Effect of Protein Binding
284
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
284


